Viewing Study NCT02542293

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-25 @ 1:15 AM
Ignite Modification Date: 2026-02-21 @ 11:08 AM
Study NCT ID: NCT02542293
Status: ACTIVE_NOT_RECRUITING
Last Update Posted: 2025-09-16
First Post: 2015-08-26
Is NOT Gene Therapy: True
Has Adverse Events: True
Brief Title: Study of Durvalumab With Tremelimumab Versus SoC as 1st Line Therapy in Metastatic Non Small-Cell Lung Cancer (NSCLC) (NEPTUNE)
Sponsor: AstraZeneca
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Non Small Cell Lung Carcinoma NSCLC View
Keywords:

Keywords

Keyword Brief Keyword Text View
None NSCLC View
None PDL1 View
None TMB View
None MEDI4736 View
None Durvalumab View
None Tremelimumab View
None OS View